In the fight against cancer, clinical trials and the ability to receive advanced treatments can provide hope for patients. However, despite the multitude of trials conducted annually in the United States, only a small fraction of eligible patients, ranging from 3% to 5%, actually enroll in these trials. The primary bottleneck lies in the cumbersome process of matching patients with appropriate trials, exacerbated by the time constraints faced by busy oncologists and nurses.
Triomics, an AI startup, aims to address this critical issue with its groundbreaking technology. Founded by former MIT biotech researcher Sarim Khan and AI scientist Hrituraj Singh, Triomics leverages the power of generative AI and large language models (LLMs) to streamline matching patients with clinical trials. Recognizing the potential of AI in healthcare, Khan and Singh embarked on their mission in 2021, driven by personal experiences and a commitment to improving patient outcomes.
Triomics’ flagship product, OncoLLM, is tailored for cancer centers and oncology departments within hospital systems. By analyzing electronic health records (EHR), OncoLLM can rapidly extract relevant data, slashing the time needed for manual review from hours to minutes. This breakthrough enables medical staff to efficiently identify suitable clinical trials based on a patient’s specific criteria, such as cancer stage, mutations, and previous treatments.
The impact of Triomics’ technology extends far beyond expediting clinical trial matching. Beyond aiding in patient enrollment, OncoLLM assists healthcare professionals in various aspects of cancer care. From facilitating pre-visit preparations to generating comprehensive cancer data for regulatory submissions, the platform enhances operational efficiency and enables more personalized patient care.
Triomics’ success has not gone unnoticed. Since its inception, the startup has garnered significant traction, with six cancer centers and hospitals already leveraging or piloting OncoLLM. Bolstered by a recent $15 million Series A funding round led by Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics is poised for further expansion. With plans to double its customer base by the year’s end, the company is committed to advancing its platform and making it accessible to more healthcare providers. Khan says that while others are also doing AI clinical trial matching, Triomics is the one of the few that does it with large datasets.